Population pharmacokinetic/pharmacodynamic analyses of pemetrexed and neutropenia: Effect of vitamin supplementation and differences between Japanese and Western Patients

Clinical Cancer Research

Volumn 15, Issue 1, 2009, Pages 346-354

  Latz, Jane E ^a   Schneck, Karen Lee ^a   Nakagawa, Kazuhiko ^b   Miller, Mary Alice ^a   Takimoto, Chris H ^c  

^a ELI LILLY AND COMPANY   (United States)

^b KINKI UNIVERSITY   (Japan)

^c South Texas Accelerated Research Therapeutics   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CYANOCOBALAMIN; CYSTATHIONINE; DEXAMETHASONE; FOLIC ACID; HOMOCYSTEINE; METHYLMALONIC ACID; PEMETREXED;

ADULT; AGED; ARTICLE; BODY SURFACE; DISEASE COURSE; DISEASE DURATION; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG MEGADOSE; ETHNIC GROUP; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NEUTROPHIL COUNT; PRIORITY JOURNAL; RACE DIFFERENCE; RASH; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; ASIAN CONTINENTAL ANCESTRY GROUP; DIETARY SUPPLEMENTS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FOLIC ACID; GLUTAMATES; GUANINE; HUMANS; MALE; MIDDLE AGED; NEUTROPENIA; TIME FACTORS; VITAMIN B 12;

EID: 58849120056     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-0791     Document Type: Article

References (32)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21:2636-44.
2. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004; 22: 1589-97.
3. Scagliotti G, Parik P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008 May 27. Epub ahead of print.
4. O'Dwyer PJ, Nelson K. Thornton DE. Overview of phase II trials of MTA in solid tumors [review]. Semin Oncol 1999; 26:99-104.
5. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003; 21:1556-61.
6. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small-cell lung cancer: a phase II study. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1999;17:1194-9.
7. Paz-Ares L, Tabernero J, Moyano A, et al. Significant activity of the multi-targeted antifolate MTA (LY231514) in advanced transitional cell carcinoma (TCC) of the bladder: results of a phase II trial [abstract]. Eur J Cancer 1999; 35:S81.
8. Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001; 85:649-55.
9. Spielmann M, Martin M, Namer M, duBois A, Unger C, Dodwell DJ. Activity of pemetrexed (ALIMTA, multitargeted antifolate, LY231514) in metastatic breast cancer patients previously treated with an anthracycline and a taxane: an interim analysis. Clin Breast Cancer 2001; 2:47-51.
10. Goedhals L, van Wiyk AL, Smith BL, Fourie SJ. Pemetrexed (Alimta, LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gynecol Cancer 2006; 16:1172-8.
11. Cripps C, Burnell M, Jolivet J, et al. Phase II study of first-line LY231514 (multi-targeted antifolate) in patients with locally advanced or metastatic colorectal cancer: an NCIC Clinical Trials Group study. Ann Oncol 1999; 10:1175-9.
12. Miller KD, Picus J, Blanke C, et al. Phase II study of the multitargeted antifolate LY231514 (ALIMTA, MTA, pemetrexed disodium) in patients with advanced pancreatic cancer. Ann Oncol 2000;11:101 -3.
13. Adjei AA. Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent [review]. Clin Cancer Res 2004; 10:4276-80S.
14. Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001; 6: 363-73.
15. Schultz RM, Patel VF, Worzalla JF, Shih C Role of thymidylate synthase in the antitumor activity of the multitargeted antifolate, LY231514. Anticancer Res 1999; 19:437-43.
16. Shih C, Chen VJ, Gossett LS, et al. LY231514, a pyr- rolo[2,3-d.] pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res 1997; 57:1116 - 23.
17. Niyikiza C, Baker SD, Seitz DE, et al. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52.
18. Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol 2002; 20:4713-21.
19. Kloft C, Wallin J, Henningsson A, Chatelut E, Karlsson MO. Population pharmacokinetic-pharmacodynamic model for neutropenia with patient subgroup identification: comparison across anticancer drugs. Clin Cancer Res 2006; 12:5481 -90.
20. Latz JE, Karlsson MO, Rusthoven JJ, Ghosh A, Johnson RD. A semimechanistic-physiologic population pharmacokinetic/pharmacodynamic model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006; 57:412-26.
21. Latz JE, Rusthoven JJ, Karlsson MO, Ghosh A, Johnson RD. Clinical application of a semimechanistic-physiologic population PK/PD model for neutropenia following pemetrexed therapy. Cancer Chemother Pharmacol 2006; 57:427 - 35.
22. Shargel L, Yu ABC. Applied biopharmaceutics and pharmacokinetics. 2nd ed. Norwalk (CT): Appleton- Century-Crofts; 1985. p. 310-2.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16:31 -41.
24. Takimoto CH, Hammond-Thelin LA, Latz JE, et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 2007; 13:2675-83.
25. Ensminger AH, Ensminger ME, Konlande JE, Robson JRK. The concise encyclopedia of foods and nutrition 2nd ed. New York: CRC-Press; 1993.
26. Goldbeck N, Goldbeck D. The healthiest diet in the world. New York: Plume (Penguin Putnam); 2001. p. 378-80
27. Shirao K, Hoff PM, Ohtsu A, et al. Comparison of the efficacy, toxicity, and pharmacokinetics of a uracil/tegafur (UFT) plus oral leucovorin (LV) regimen between Japanese and American patients with advanced colorectal cancer: joint United States and Japan study of UFT/LV. J Clin Oncol 2004; 22 3466 - 74.
28. Schimmer BP, Parker KL Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones In: Brunton LL, Lazo JS, Parker KL, editors Goodman & Gilman's the pharmacological basis of therapeutics. 11th ed. New York McGraw-Hill Professional; 2005. p 1587-612
29. Rinaldi DA, Kuhn JG, Burris HA, et al. A phase I evaluation of multitargeted antifolate (MTA, LY231514), administered every 21 days, utilizing the modified continual reassessment method for dose escalation. Cancer Chemother Pharmacol 1999; 44 372-80.
30. Nakagawa K, Kudoh S, Matsui K, et al. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B12 in Japanese patients with solid tumours. Br J Cancer 2006; 95:677-82
31. Cullen MH, Zatloukal P, Sörenson S, et al A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non- small-cell lung cancer. Ann Oncol 2008; b19:939-45
32. 2 of pemetrexed in patients (pts) with locally advanced or metastatic non-small cell lung cancer (NSCLC) who had prior chemotherapy [abstract]. J Clin Oncol 2007; 25:406S.